Artelo Biosciences terminates at-the-market offering agreement

Artelo Biosciences Inc. (NASDAQ: ARTL) terminated its at-the-market offering agreement with R.F. Lafferty & Co., Inc., the company announced. The termination notice was provided on May 11, 2026, with the agreement ending on May 18, 2026.

The sales agreement, originally dated July 18, 2025, allowed Artelo to sell up to $6,500,000 worth of common stock through R.F. Lafferty in an at-the-market equity offering program. Under the arrangement, the company could offer and sell shares of its common stock with a par value of $0.001 per share at various times.

Through May 11, 2026, Artelo sold 50,858 shares of common stock under the agreement, generating gross proceeds of $451,526.95. The termination follows the terms outlined in the original sales agreement.

The information is based on a company statement.

You May Also Be Interested In

• BuzzFeed sells shares to Byron Allen affiliate for $5.8 million
• Catheter Precision (VTAK) files for 68.07M share offering by selling stockholders
• Montana-Dakota Utilities signs power deal with Applied Digital for 430 MW AI campus